Journal article
Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naive youth in the HIV Research Network
HIV medicine, v 20(2)
01 Feb 2019
PMID: 30561888
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Objectives Several single-tablet regimens (STRs) are now available and are recommended for first-line antiretroviral therapy (ART); however, STR use for youth with HIV (YHIV) has not been systematically studied. We examined the characteristics associated with initiation of STRs versus multi-tablet regimens (MTRs) and the virological outcomes for youth with nonperinatally acquired HIV (nPHIV). Methods A retrospective cohort study of nPHIV youth aged 13-24 years initiating ART between 2006 and 2014 at 18 US HIV clinical sites in the HIV Research Network was performed. The outcomes measured were initiation of STRs versus MTRs, virological suppression (VS) at 12 months, and time to VS. Demographic and clinical factors associated with initiation of STR versus MTR ART and VS (mL) at 12 months after initiation were assessed using multivariable logistic regression. Cox proportional hazards regression was used to assess VS within the first year. Results Of 987 youth, 67% initiated STRs. Of the 589 who had viral load data at 1 year, 84% of those on STRs versus 67% of those on MTRs achieved VS (P < 0.01). VS was associated with STR use [adjusted odds ratio (AOR) 1.61; 95% confidence interval (CI) 1.01-2.58], white (AOR 2.41; 95% CI 1.13-5.13) or Hispanic (AOR 2.38; 95% CI 1.32-4.27) race/ethnicity, and baseline CD4 count 351-500 cells/mu L (AOR 1.94; 95% CI 1.18-3.19) and > 500 cells/mu L (AOR 1.76; 95% CI 1.0-3.10). STR use was not associated with a shorter time to VS compared with MTR use [hazard ratio (HR) 1.07; 95% CI 0.90-1.28]. Conclusions Use of STR was associated with a greater likelihood of sustained VS 12 months after ART initiation in YHIV.
Metrics
Details
- Title
- Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naive youth in the HIV Research Network
- Creators
- D. C. Griffith - Johns Hopkins MedicineC. Farmer - Johns Hopkins MedicineK. A. Gebo - Johns Hopkins MedicineS. A. Berry - Johns Hopkins MedicineJ. Aberg - Icahn School of Medicine at Mount SinaiR. D. Moore - Johns Hopkins MedicineA. H. Gaur - St. Jude Children's Research HospitalW. C. Mathews - University of California, San DiegoR. Beil - Montefiore Medical CenterP. T. Korthuis - Oregon Health & Science UniversityA. E. Nijhawan - The University of Texas Southwestern Medical CenterR. M. Rutstein - Children's Hospital of PhiladelphiaA. L. Agwu - Johns Hopkins MedicineHoward Edelstein - Alameda Cty Med Ctr, Oakland, CA USARichard Rutstein - Children's Hospital of PhiladelphiaAmy Baranoski - Drexel UniversitySara Allen - Drexel UniversityStephen Boswell - Fenway Hlth, Boston, MA USAKenneth Mayer - Fenway Hlth, Boston, MA USAKelly Gebo - Johns Hopkins MedicineRichard Moore - Johns Hopkins MedicineAllison Agwu - Johns Hopkins MedicineRobert Beil - Montefiore Medical CenterUriel Felsen - Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USAJudith Aberg - Icahn School of Medicine at Mount SinaiAntonio Urbina - Mt Sinai St Lukes & Mt Sinai West, New York, NY USAP. Todd Korthuis - Oregon Health & Science UniversityAnk Nijhawan - The University of Texas Southwestern Medical CenterMuhammad Akbar - Parkland Hlth & Hosp Syst, Dallas, TX USAAditya Gaur - St. Jude Children's Research HospitalCharurut Somboonwit - Tampa Gen Hlth Care, Tampa, FL USAWilliam Valenti - Trillium Hlth, Rochester, NY USAW. Christopher Mathews - University of California, San DiegoHIV Res Network
- Publication Details
- HIV medicine, v 20(2)
- Publisher
- Wiley
- Number of pages
- 6
- Grant note
- HHSA290201100007C / Agency for Healthcare Research and Quality; United States Department of Health & Human Services; Agency for Healthcare Research & Quality U01 DA036935; P30 AI094189; T32AI052071 / National Institutes of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA U01DA036935 / NATIONAL INSTITUTE ON DRUG ABUSE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); European Commission AI036214 / UC San Diego Center for AIDS Research T32AI052071 / NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID) HHSH250201600009C / Health Resources and Services Administration; United States Department of Health & Human Services; United States Health Resources & Service Administration (HRSA)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- MD (Doctor of Medicine) Program; [Retired Faculty]
- Web of Science ID
- WOS:000455794800012
- Scopus ID
- 2-s2.0-85058674920
- Other Identifier
- 991019168262604721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Infectious Diseases